Nutex Health 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- For the first 9 months of 2026, total revenue was $644.9 million, down 11% from $723.6 million in the same period of 2025, and adjusted EBITDA was $211.4 million, down 13% from $243 million.
- Net income attributable to Nutex increased 159% to $152.9 million for the first 9 months of 2026 from $59 million in the same period of 2025.
- Hospitals recorded 154,300 patient visits in the first 9 months of 2026, up 10.2% from 140,100 in the same period of 2025; same-hospital growth was 6.3%.
- For Q3 2026, total revenue was $217.6 million versus $267.8 million in Q3 2025, net income attributable to Nutex was $40.2 million versus $55.4 million, and adjusted EBITDA attributable to Nutex was $63.9 million versus $98.5 million.
- Q3 hospital visits increased 18.1% year over year to 54,622, while same-hospital visits increased 12.4%.
- Cash on hand was $249.9 million as of September 30th, 2026, compared with $185.6 million at year-end 2025; net cash from operating activities was $188.1 million for the first 9 months of 2026, up from $177.7 million in 2025.
- Management attributed year-over-year revenue and adjusted EBITDA declines primarily to unusually strong revenue recognition in the first 9 months of 2025, including updated collection estimates for 2024 services and ineligible charts later adjusted in Q4 2025.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Greetings, and welcome to the Nutex Health 2026 third quarter earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Vivian Sanders.
Please go ahead. Good morning, everyone, and welcome to Nutex Health Inc.'s third quarter 2026 earnings call.
My name is Vivian Sanders, and I'm happy to serve as your moderator today. We're truly grateful for your participation and your continued interest in our company as we share the highlights of another exceptional quarter. Please note that this call is being recorded for future reference. Joining me this morning are some of our key leaders driving Nutex Health forward. Our Chairman and CEO, Dr. Tom Vo, our Chief Financial Officer, Jon Bates, our President, Dr. Warren Hosseinion, and our Chief Operating Officer, Wes Bamburg. Together, they'll provide prepared remarks to give you a comprehensive view of our performance, strategies, and vision, after which we'll open the floor for your questions. Before I turn things over to Dr. Vo, I'd like to take a moment to address a few important points.
Today's discussion may include forward-looking statements which reflect management's current expectations about our future performance. These statements are based on what we know today, but they're subject to risks, uncertainties, and other factors that could cause our actual results to differ from what we'll share. For a deeper dive into these forward-looking statements and the factors that might influence them, I encourage you to review the press release and Form 10-Q filed earlier this week, as well as our various SEC filings. You'll find all the details there. Additionally, we may reference non-GAAP financial measures such as Adjusted EBITDA during the call. For those interested in how these metrics were compiled to GAAP standards, please refer to the press release and the Form 10-Q, where we've included that information.
With those housekeeping items out of the way, it's my pleasure to hand the call over to Dr. Tom Vo, our Founder and Chief Executive Officer. Dr. Vo, the floor is yours.
Thank you, Vivian, and good morning, everyone. I am pleased to join you today to review Nutex Health's third quarter 2026 results. It was another strong quarter with solid financial results, steady collections, important reimbursement developments, and continued growth in hospital volumes. I will start with our financial and operational performance in the first nine months. For the first three quarters of 2026, total revenue reached $644.9 million, an 11% decrease from $723.6 million for the same period in 2025. Adjusted EBITDA decreased 13% from $243 million to $211.4 million for the first three quarters of 2026. Net income attributable to Nutex increased to $152.9 million for the first three quarters of 2026, a 159% increase from $59 million for the same period in 2025.
On the volume side, for the first three quarters of 2026, our hospitals recorded 154.3 thousand total patient visits, up 10.2% from 140.1 thousand during the same period in 2025. Same-hospital growth was 6.3% in the first nine months of 2026. On the balance sheet, net long-term debt went from $29.2 million at December 31, 2025, to $34.2 million at the end of Q3 2026. Still very low relative to our revenue and our expansion pace. Cash on hand grew to $249.9 million as of September 30, 2026, up from $185.6 million at year-end 2025. Net cash from operating activities was $188.1 million for the first three quarters of 2026, compared to $177.7 million in 2025, a 6% increase. Several factors supported our strong performance over the first nine months. Patient volume and acuity continued to rise, supported by renewed internal initiatives and investments.
In particular, same-hospital growth is significant for us, as it means our growth strategy is not wholly reliant on the opening of new hospitals. Earnout expenses declined as most legacy facilities under development as of 2022 completed investing, boosting net income. Arbitration-related costs decreased following the renegotiation of the HaloMD contract in the second quarter of 2026. Collections remained strong through the third quarter of 2026. Investors may have noticed a decline in both revenue and Adjusted EBITDA year-over-year through the first three quarters of 2026. The declines are not necessarily due to weaker collections in 2026, but rather due to an uneven revenue recognition for the first nine months in 2025, primarily reflected by two factors. First, additional collection data available in 2025 supported higher collection estimates for 2024 services that was recognized in 2025.
Second, ineligible charts were included from mid-2024 through the first three quarters of 2025, and adjusted in the fourth quarter of 2025. We are also starting to see slight differences between collections for hospital versus collections for the physician entity. Physician fee collections are slightly down compared to hospital collection in the third quarter. This may account for some of the decreases in revenue in addition to the factors that I mentioned above. As a reminder, physician revenue are consolidated in the revenue, but eliminated down at the net income level. We are continuing to follow this trend closely. In addition, we are seeing more stabilization of revenue this year compared to this time last year. Lastly, as more internal hospital development commences, the long-term debt would increase accordingly in future quarters. Jon will discuss these details in his report.
Turning to reimbursement, the quarter includes several developments that positively reinforce our long-term view of the No Surprises Act, NSA, and the independent dispute resolution, IDR process. First, as discussed on our last earnings call, federal courts in California, Florida, Pennsylvania, Texas, Connecticut, and Georgia issued decisions during the first half of 2026, reinforcing the finality of the IDR award and limiting insurers' ability to challenge arbitration outcomes in court. In the third quarter, the District Court in Virginia reached a similar conclusion in a case involving Blue Cross Blue Shield of Virginia, bringing the number of states with provider-favorable ruling on key IDR issues to at least seven. We believe these rulings support our view that the laws, payment, and arbitration requirements should be enforced as written.
Second, recent antitrust and consumer protection against insurers by the Kansas and Michigan attorney generals highlight intensifying regulatory challenges to the activities of insurers, focusing on plan administrative practices, in particular fiduciary management, hidden fee structures, and the lack of transparency of out-of-network pricing mechanism. Among other things, the Kansas lawsuit alleges that insurers inflate the revenue by making below-market initial out-of-network offer in the IDR process, creating an artificial cost savings to maximize the percentage-based administrative fee payable to the insurer, which is tied directly to these suppressed payment benchmarks. Third, as disclosed in our August press release, the U.S. Court of Appeals for the Fifth Circuit issued an en banc decision addressing calculation of the qualifying payment amount, or QPA, under the NSA.
The court ruled in favor of the Texas Medical Association and other plaintiffs on two of the three issues presented, invalidating the use of ghost rates in federal QPA calculations. The QPA is an important benchmark in the IDR process. We have consistently maintained that the use of ghost rates and other flawed methodologies can distort QPA calculations, contributing to substantial provider underpayment, and result in an increase in the volume of IDR disputes. We view the court's decision as a meaningful progress toward a more transparent and balanced reimbursement framework. Over time, more accurate upfront payments without the use of ghost rates should reduce the rate for costly and time-consuming arbitration. Fourth, earlier this month, CMS released the results of two latest formal audits, including CareSource of Indiana and the School Employees Retirement System of Ohio.
In the CareSource audit, CMS identified deficiencies involving required NSA disclosures, timely delivery of QPA-related information, and calculation of the QPA under applicable regulations. The School Employees Retirement System audit similarly identified deficiencies involving the lack of appropriate QPA disclosures and IDR-related notification requirements. These findings provide further evidence of inconsistent insurer compliance and payment practices, including continued non-compliance with federal guidelines. We believe stronger oversight and enforcement can help providers receive more timely and accurate reimbursement. Fifth, we are closely monitoring the legislative developments in Washington, D.C., including two recent proposals that take materially different approaches to the future of the IDR framework. The Murphy bill would preserve independent arbitration while strengthening enforcement mechanisms and adding penalties for payers that do not timely satisfy IDR awards. We strongly support the Murphy bill and are advocating for its passage.
The Pallone bill, by contrast, would eliminate the IDR process beginning in 2028 and generally make the payer-calculated QPA the final reimbursement amount for out-of-network services, with limited review of the methodology used to calculate those rates. We firmly oppose the Pallone proposal. We believe the independent review through the current IDR process is essential when insurer MAC reimbursement rates fail to reflect the fair market values, as they currently do most of the time. We also expect strong opposition from other provider organizations should the legislation advance. We are also aware of other non-emergency specialties, physician specialties, including anesthesiology, surgery, radiology, and medical transportation companies that also use the IDR to seek fair reimbursement, though we are unfamiliar with their outcomes or eligibility. While the Pallone proposal's intended target is the overall IDR process, it is unclear to us which specialty he is targeting.
We suspect that the Pallone bill may aim to limit other non-emergency providers' access to the IDR. Federal and state EMTALA requirements obligate our hospitals to evaluate every single patient that enters our emergency rooms. We expect, similarly, insurers to meet their federal obligations under the Prudent Layperson Act by paying fair and reasonable reimbursement to EMTALA-participating hospitals and emergency medicine providers. We also have no control over other providers that provide non-emergency services. Nutex's goal is very simple. We seek fair, market-based reimbursement for medically necessary care in our communities, with comparable payment for comparable services in comparable settings. Federal laws enacted to achieve this result should be enforced and median in-network rates calculated accurately without ghost rates distortions. Turning to growth, we remain confident in our hospitals' development pipeline and the opportunities ahead.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
